Redeye notes improved cost control in the preliminary Q2 figures, and sales in line with our lowered estimates.
Redeye adjusts its fair value range following the announcement of the rights issue.
Redeye is surprised by the low 69% acceptance rate from Integrum’s shareholders on the SEK44 bid by Osteocentric.
Redeye argues that the relatively disappointing quarterly figures increase the likelihood of the shareholders accepting the SEK44 bid offer.
Redeye provides its preview of Integrum’s Q1 2025 report, due on Monday, September 1.
Redeye comments on the takeover bid from OsteoCentric.
Redeye returns with a more in-depth take on the Q4 results.
Redeye leaves its initial comments on Integrum’s Q4 report.
Redeye provides its preview of Integrum’s Q4 2024 report, due on Tuesday, June 3.
Redeye returns with a more in-depth take on the Q3 results.
Redeye leaves its initial comments on Integrum’s Q3 report.
Redeye comments on Integrum’s directed share issue and we adjust our fair value range per the new number of shares and injected funds.
Redeye comments on the evening’s news regarding Integrum’s strategic shift for accelerating OPRA commercialisation, its preliminary Q3 figur...
Redeye is encouraged by the recent news regarding Integrum’s increased educational activities, together with a strong partner in the field.
Redeye comments on the recent news regarding Integrum’s partnership with Intelerad.
Redeye returns with a more in-depth take on the report following the conference call and chat with management.
Redeye sees a Q2 report in line with our sales expectations but a bit heavier on the cost side.
Redeye provides a preview for Integrum’s Q2 report, due on Wednesday, December 4.
Redeye briefly comments on the recent management change in Integrum.
Redeye returns with a more detailed take on the Q1 report.
Redeye expects the Integrum share to trade down considerably during the day.
Redeye provides a preview for Integrum’s Q1 report, due on Thursday, August 29.
Redeye embraces the not-so-unanticipated SEK50m directed share issue, giving the company additional buffer for its growth activities.
Redeye embraces the collaboration with Hanger, a leading amputee care and prosthetics provider with a 25-30% market share of the orthotic an...
Redeye reviews the Integrum case and provides a more clear-cut take on its longer-term outlooks.
Redeye sees weaker-than-expected US sales, and while this certainly spooked the stock market, we argue that the long-term outlooks for Integ...
Redeye provides a preview for Integrum’s Q4 report, due on Thursday, May 30.
Redeye sees a quarter developing per our expectations, and we make no estimate revisions.
Redeye believes Integrum has good prospects of continuing to deliver positive EBIT during its high sales growth phase for the coming years.
Redeye goes through and gives comments on Integrum’s latest news flow.
Redeye argues that the recent news regarding Integrum’s review and evaluation of strategic alternatives leaves more questions than answers a...
Redeye is encouraged to see Integrum delivering well on sales throughout the challenging summer months.
Redeye provides an updated take on its outlooks for Integrum.
Redeye returns with a more detailed take on Integrum’s Q3 report.
Redeye provides a brief take on Integrum’s Q3 report, and we note a -20% deviation from our sales estimates, resulting in a miss on our oper...
Redeye notes another quarter where Integrum is delivering well on its organizational and commercial intensification with a clear US focus, w...
Redeye returns with a more in-depth take on the Q4’21/22 report and is encouraged that Integrum demonstrated significant sales growth.
Redeye returns with a more in-depth take of the Q3’21 report, which reflected a relatively neutral financial development.
Redeye provides its initial take on the Q3’21 report and has a relatively neutral view all in all.
Redeye embraces today’s report, showing record-high net sales in the quarter, and anticipates a continued positive trajectory.
